Related Experiment Video
Updated: Feb 14, 2026

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial
Ozlem Aslan1, Mattia Cremona2, Clare Morgan2
1Department of Medical Oncology, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin 9, Ireland. ozlemasl@gmail.com.
Background:
The phosphoinositide-3-kinase (PI3K) pathway is the most commonly activated pathway in cancers due to mutations at multiple nodes and loss of PTEN. Furthermore, in endometrial cancer (EC), PI3K and RAS/RAF/MEK/MAPK (RAS/MAPK herein) pathway mutations frequently co-exist. We examined the role of PI3K and RAS/MAPK pathway mutations in determining responsiveness to therapies targeted to these pathways in vitro in EC.
Methods:
13 EC cell lines were profiled for their PI3K pathway and KRAS mutational and PTEN protein status and treated with one MEK- and two PI3K- targeted inhibitors alone and in combination. Expression and phosphorylation of 66 proteins were evaluated by Reverse-Phase-Protein-Array (RPPA) in 6 EC cell lines to identify signalling changes in these pathways in response to therapy.
Results:
PTEN protein loss and the absence of any tested pathway mutations are dominant negative predictors of sensitivity to MEK inhibition. KRAS-mutated cells were most sensitive to MEK inhibition, but significantly more resistant to PI3K inhibition than KRAS-wild-type cell lines. Combinations of PI3K and MEK inhibitors showed synergy or additivity in all but two cell lines tested. Treatment of KRAS-mutated cells with PI3K inhibitors and treatment of PTEN-low cells with a MEK inhibitor were most likely to induce activation of MEK/MAPK and AKT, respectively, likely indicative of feedback-loop regulation.
Conclusions:
MEK inhibition may be a promising treatment modality, not just for ECs with mutated KRAS, but also for those with retained PTEN. Up-regulation of MEK/MAPK signalling by PI3K inhibition, and up-regulation of AKT activation by MEK inhibition may serve as potential biomarkers of likely responsiveness to each inhibitor.
Insights
Targeting the phosphoinositide-3-kinase (PI3K) and RAS/MAPK pathways shows promise in endometrial cancer (EC). MEK inhibition is effective for KRAS-mutated and PTEN-retained EC, with potential biomarkers identified.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- The phosphoinositide-3-kinase (PI3K) pathway is frequently activated in cancers, including endometrial cancer (EC).
- Mutations in PI3K and RAS/RAF/MEK/MAPK (RAS/MAPK) pathways often co-occur in EC.
- PTEN loss is a common event contributing to PI3K pathway activation.
Purpose of the Study:
- To investigate the role of PI3K and RAS/MAPK pathway mutations in EC.
- To determine the responsiveness of EC cell lines to targeted therapies against PI3K and MEK pathways.
- To identify potential biomarkers for predicting treatment response.
Main Methods:
- Profiling of 13 EC cell lines for PI3K pathway, KRAS mutations, and PTEN protein status.
- Treatment with MEK and PI3K inhibitors, alone and in combination.
- Analysis of signaling pathway changes using Reverse-Phase-Protein-Array (RPPA).
Main Results:
- PTEN loss and absence of mutations predicted poor response to MEK inhibition.
- KRAS-mutated cells were sensitive to MEK inhibitors but resistant to PI3K inhibitors.
- Combinations of PI3K and MEK inhibitors demonstrated synergy or additivity in most cell lines.
- Feedback activation of MEK/MAPK and AKT pathways was observed in response to PI3K and MEK inhibition, respectively.
Conclusions:
- MEK inhibition is a potential treatment for EC, particularly for tumors with mutated KRAS or retained PTEN.
- Up-regulation of MEK/MAPK and AKT signaling may serve as predictive biomarkers for PI3K and MEK inhibitors, respectively.
- Targeting these pathways offers a promising therapeutic strategy for endometrial cancer.
Related Concept Videos
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
PI3K/mTOR/AKT Signaling Pathway
Phase Transitions: Sublimation and Deposition
Phase Diagrams
Phase Transitions
Phase Transitions: Melting and Freezing

